KRRO
Korro Bio, Inc.Healthcare·Biotechnology
$13.41
$133M market cap
Revenue
$1.3M
Free Cash Flow
$-33.9M
Rev Growth
+0.0%
FCF Margin
-2622.4%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
2-Year Price History
$11.61-77.4%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -20.1 | -20.4 | -19.6 | -16.1 | -16.1 | -0.0 | 114.0 | 42.9 | 11.6 | -64.1% | -- | -- |
| Act | 2025-Q4 | 1.3 | -15.2 | -15.9 | -50.0 | -17.7 | -17.8 | -0.1 | 75.2 | 43.5 | 9.4 | -105.5% | -- | -- |
Valuation & Metrics
Market Stats
Price$13.41
Market Cap$133M
Enterprise Value$62M
P/S Ratio103.3x
P/FCF--
EV/FCF--
FCF Margin (TTM)-2622.4%
FCF Yield-25.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$1.3M
Net Income$-69.7M
Free Cash Flow$-33.9M
Revenue Growth (YoY)+0.0%
EBITDA Margin-2731.4%
Net Margin-5392.2%
FCF Margin-2622.4%
CapEx % of Revenue8.1%
SBC % of Revenue371.7%
ROIC-84.8%
WC Change % Rev98.7%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares1.1M
Days to Cover15.7
Change (vs Prior)+3.0%
Need at least 2 settlement dates for chart
Employees
Headcount112
Revenue / Employee$11,536
Gross Profit / Employee$2,348
Cash Runway
40.4months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
115.8%(-18.7% YoY)
86 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
13.7%(-4.3% YoY)
8 filers
Vanguard, iShares, SPDR
Market makers
1.4%(+1.2% YoY)
4 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | $17.4M | $9.93 | +$9.7M | +$17.4M | +3.0% | $633M |
| NEA Management Company, LLC | $14.7M | $41.89 | +$2.3M | +$2.3M | -3.3% | $1.76B |
| Atlas Venture Life Science Advisors, LLC | $12.9M | $47.71 | +$0 | +$0 | +2.2% | $790M |
| BALYASNY ASSET MANAGEMENT LLC | $11.8M | $11.66 | +$11.7M | +$11.8M | -0.4% | $48.01B |
| VR Adviser, LLC | $11.4M | $11.32 | +$11.4M | +$11.4M | -1.9% | $2.68B |
| Affinity Asset Advisors, LLC | $8.0M | $11.32 | +$8.0M | +$8.0M | +0.5% | $1.60B |
| Nantahala Capital Management, LLC | $7.5M | $8.31 | +$680K | +$7.5M | -2.4% | $1.60B |
| ADAR1 Capital Management, LLC | $6.1M | $13.76 | +$5.7M | +$5.3M | +8.4% | $1.64B |
| BlackRock, Inc.Passive | $5.2M | $31.89 | +$30K | +$210K | -0.2% | $5.69T |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $5.1M | $35.72 | −$2.5M | −$1.5M | +0.3% | $13.60B |
| TCG Crossover Management, LLC | $4.7M | $47.89 | +$0 | +$4.7M | +4.6% | $3.50B |
| Siren, L.L.C. | $3.9M | $33.42 | +$0 | −$805K | +6.2% | $3.61B |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $3.5M | $11.32 | +$3.5M | +$3.5M | — | $4.04T |
| 72 Investment Holdings, LLC | $3.1M | $47.93 | +$0 | +$0 | -14.7% | $49.6M |
| AQR CAPITAL MANAGEMENT LLC | $3.0M | $17.75 | +$2.6M | +$3.0M | -0.2% | $218.19B |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.6M | $11.32 | +$2.6M | +$2.6M | -0.1% | $64.61B |
| GEODE CAPITAL MANAGEMENT, LLCPassive | $2.0M | $35.80 | +$123K | +$378K | +2.3% | $1.61T |
| TWO SIGMA INVESTMENTS, LP | $1.9M | $18.23 | +$979K | +$1.9M | -0.9% | $117.03B |
| VANGUARD PORTFOLIO MANAGEMENT LLCPassive | $1.7M | $11.32 | +$1.7M | +$1.7M | — | $1.91T |
| STATE STREET CORPPassive | $1.6M | $35.70 | −$67K | +$203K | -0.2% | $2.89T |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)NEUTRAL
Holders
+0.26%
avg per quarter
Holders (ex-self)
+0.34%
excl. this stock
Buyers (this Q)
+0.17%
58 buyers · $0.08B in
Sellers (this Q)
+0.27%
23 sellers · $0.03B out
alpha coverage: 96% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-1.7%
how holders react when this stock falls
On quiet Qs
-2.0%
−10% to +10% baseline
On rallies (+10%+)
-1.8%
how they react when this stock rises
Holders' portfolio flow this Q
+3.8%
inflows — adds are organic
Sellers' portfolio flow this Q
-10.4%
Sellers shed AUM broadly — partly forced.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-4.3%
Holder mid (any stock)
-4.8%
Holder rally (any stock)
-6.3%
Biggest decreases this quarter
DRIEHAUS CAPITAL MANAGEMENT LLC−$2.5Mα+0.3JANE STREET GROUP, LLC−$2.0Mα-0.1SUSQUEHANNA INTERNATIONAL GROUP, LLPexited−$1.6MMILLENNIUM MANAGEMENT LLC−$1.1Mα-0.5Graham Capital Management, L.P.exited−$327KSIMPLEX TRADING, LLCexited−$226KAMERICAN CENTURY COMPANIES INCexited−$85KJain Global LLCexited−$85KSTATE STREET CORP−$67Kα-0.2BANK OF AMERICA CORP /DE/exited−$47K
New buyers this quarter
Top-5 holders · 47.1%
Lynx1 Capital Management LP--
NEA Management Company, LLC--
Atlas Venture Life Science Advisors, LLC--
BALYASNY ASSET MANAGEMENT LLC--
VR Adviser, LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Atlas Venture Life Science Advisors, LLC1.1MNEA Management Company, LLC1.3MFMR LLC39KEVENTIDE ASSET MANAGEMENT, LLC—Cormorant Asset Management, LLC—CITADEL ADVISORS LLC31KArtal Group S.A.—Deep Track Capital, LP—Qiming U.S. Ventures Management, LLC—DRIEHAUS CAPITAL MANAGEMENT LLC450K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (3 analysts)$20.004910.0%
Last Year (10 analysts)$19.604620.0%
Current Price$13.41
Analyst Ratings
10
2
Buy: 10Hold: 2Consensus: Buy
Corporate
Insider Trading (last 12mo)
Open-market only (Form 4 P-Purchase + S-Sale). Excludes grants, option exercises, tax withholding, gifts.
Major holders (≥10% beneficial owners)
Buys ($, 12mo)
$20.72M
10 txns · 10 insiders · 4,050,925 sh
Sells ($, 12mo)
$0
0 txns · 0 insiders · 0 sh
Recent transactions
| Date | Side | Insider | Title | Shares | Price | Dollars | Owned $ |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | BUY | Lynx1 Capital Management LP | 10 percent owner | 520 | $10.60 | $6K | $16.31M |
| 2026-03-10 | BUY | BASKETT FOREST | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Chang Carmen | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Florence Anthony A. Jr. | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Makhzoumi Mohamad | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Mathers Edward T | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | New Enterprise Associates 17, L.P. | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | SANDELL SCOTT D | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Walker Paul Edward | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
| 2026-03-10 | BUY | Yang Rick | 10 percent owner | 450,045 | $5.11 | $2.30M | $6.64M |
Order Flow (FINRA, ~3w lag)
13.6%retail-2.7pp
23.2%dark-0.8pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Korro Bio, Inc.: Clinical Collapse Meets Terminal Dilution
Overall Risk
8/10
Fraud
3/10
Dilution
9/10
Insolvency
8/10
Earnings Overstated
4/10
Hidden Liabilities
5/10
Legal
2/10
Audit Warnings
6/10
Hidden Upside
2/10
Contextually Acceptable
4/10